CA2609985A1 - Modulation des dysfonctionnements de la barriere cellulaire - Google Patents

Modulation des dysfonctionnements de la barriere cellulaire Download PDF

Info

Publication number
CA2609985A1
CA2609985A1 CA002609985A CA2609985A CA2609985A1 CA 2609985 A1 CA2609985 A1 CA 2609985A1 CA 002609985 A CA002609985 A CA 002609985A CA 2609985 A CA2609985 A CA 2609985A CA 2609985 A1 CA2609985 A1 CA 2609985A1
Authority
CA
Canada
Prior art keywords
opioid receptor
opioid
aeruginosa
receptor antagonist
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002609985A
Other languages
English (en)
Inventor
John C. Alverdy
Jonathan Moss
Mark W. Lingen
Patrick A. Singleton
Joe G.N. Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
The University Of Chicago
John C. Alverdy
Jonathan Moss
Mark W. Lingen
Patrick A. Singleton
Joe G.N. Garcia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/007892 external-priority patent/WO2006096626A2/fr
Application filed by The University Of Chicago, John C. Alverdy, Jonathan Moss, Mark W. Lingen, Patrick A. Singleton, Joe G.N. Garcia filed Critical The University Of Chicago
Publication of CA2609985A1 publication Critical patent/CA2609985A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002609985A 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire Abandoned CA2609985A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US68756805P 2005-06-03 2005-06-03
US60/687,568 2005-06-03
US73100905P 2005-10-28 2005-10-28
US60/731,009 2005-10-28
US76085106P 2006-01-20 2006-01-20
US60/760,851 2006-01-20
USPCT/US2006/07892 2006-03-07
PCT/US2006/007892 WO2006096626A2 (fr) 2005-03-07 2006-03-07 Utilisation d'antagonistes opioides pour l'attenuation de la proliferation et de la migration des cellules endotheliales
PCT/US2006/021604 WO2007053194A2 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire

Publications (1)

Publication Number Publication Date
CA2609985A1 true CA2609985A1 (fr) 2007-05-10

Family

ID=38006351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002609985A Abandoned CA2609985A1 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire

Country Status (3)

Country Link
EP (1) EP1901742A2 (fr)
CA (1) CA2609985A1 (fr)
WO (1) WO2007053194A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1615646E (pt) 2003-04-08 2015-02-12 Progenics Pharm Inc Formulações farmacêuticas com metilnaltrexona
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
JP2009534384A (ja) * 2006-04-19 2009-09-24 ジル・ピー・スミス オピオイドアンタゴニストによる炎症性および潰瘍性腸疾患の治療
EP2134718A2 (fr) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Formes cristallines, et leurs utilisations
EP2137191B8 (fr) 2007-03-29 2016-06-08 Progenics Pharmaceuticals, Inc. Antagonistes de récepteurs opioïdes périphériques, et leurs utilisations
DK2565195T3 (en) 2007-03-29 2015-06-29 Wyeth Llc PERIPHERAL OPIOID RECEPTOR AND ANTAGONISTS AND USES THEREOF
RU2440117C1 (ru) * 2007-10-05 2012-01-20 Торэй Индастриз, Инк. Терапевтическое средство для улучшения свойств кожи, включающее в качестве действующего ингредиента производное морфинана или любую из его фармакологически приемлемых кислотно-аддитивных солей
JP5358587B2 (ja) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
EP2306829B1 (fr) 2008-07-01 2017-01-04 University of Chicago Particules contenant un antagoniste périphérique de récepteur d'opioïde
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
ES2951828T3 (es) 2010-09-23 2023-10-25 Leading Biosciences Inc Administración de inhibidores de serina proteasa al estómago
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
CN112641771B (zh) 2014-03-25 2022-04-15 恒翼生物医药科技(上海)有限公司 用于治疗自身消化的组合物
CN117940554A (zh) * 2022-06-30 2024-04-26 上海羽冠生物技术有限公司 假单胞菌属的活细菌菌株

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
MX2007015262A (es) * 2005-06-03 2008-02-22 Univ Chicago Modulacion de interacciones de celulas huesped de patogenos microbianos.

Also Published As

Publication number Publication date
EP1901742A2 (fr) 2008-03-26
WO2007053194A2 (fr) 2007-05-10
WO2007053194A3 (fr) 2007-08-09

Similar Documents

Publication Publication Date Title
US20140142133A1 (en) Modulation of cell barrier dysfunction
CA2609985A1 (fr) Modulation des dysfonctionnements de la barriere cellulaire
AU2012272815B2 (en) Treatment of proteinopathies
AU2006255274A1 (en) Modulation of microbial pathogen-host cell interactions
Ye et al. Scutellarin inhibits caspase-11 activation and pyroptosis in macrophages via regulating PKA signaling
JP2020524706A (ja) 結節性硬化症複合体の処置におけるカンナビジオールの使用
US7105576B2 (en) Synergistic effects of nuclear transcription factor NF-κB inhibitors and anti-neoplastic agents
Urbauer et al. Mitochondrial metabolism in the intestinal stem cell niche—sensing and signaling in health and disease
AU2006341983A1 (en) Use of an NMDA receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity
Clark et al. Inhibition of protein kinase C attenuates Pseudomonas aeruginosa elastase–induced epithelial barrier disruption
Hyun et al. Potential role of Hedgehog signaling and microRNA-29 in liver fibrosis of IKKβ-deficient mouse
JP2019513749A (ja) 衛生化及び麻酔用のｔｒｐｖ４及びｔｒｐａ１の小分子二重阻害剤
Broadley et al. Effects of dietary amines on the gut and its vasculature
US20090186949A1 (en) Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds
EP3810272A1 (fr) Compositions et procédés pour la réduction ou le traitement de la fibrose
Shimazu et al. (−)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release
JP2014208673A (ja) オピオイド拮抗薬による薬物誘発性嘔気の治療
KR20220041134A (ko) 세로토닌성 제제 및 5-ht1a-수용체 길항제
EP2599488B1 (fr) Vicenin 2 et dérivés associés à utiliser en tant qu'agent antispasmodique et/ou prokinétique
Su et al. Evaluation of the Effects of E-Cigarette Aerosol Extracts and Tobacco Cigarette Smoke Extracts on Human Gingival Epithelial Cells
KR20100016524A (ko) 히스톤 데아세틸라제의 억제제에 대한 약리효능 바이오마커로서의 칼슘 플럭스
KR20230019387A (ko) 호노키올을 포함하는 조성물 및 이의 내피 기능장애 질환의 예방, 개선 및 치료 용도
WO2023154014A1 (fr) Antagonistes nmdar prévenant le vieillissement et les troubles et maladies associées au vieillissement en augmentant l'activité du protéasome 20s
Bradbury The Role of Serotonin in MDMA Self-administration in rats
JP2012102069A (ja) 早漏治療剤

Legal Events

Date Code Title Description
FZDE Dead